Marina Pavanello

Very excited to share our review of rare inherited mutations in #ovariancancer really focussing on the differences between each histotype. @UNSWMedicine Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer mdpi.com/862832 via @MDPIOpenAccess

The first episode of the new podcast from the Portuguese Society for Immunology, where @BSilva_Santos discusses cancer immunotherapy, is now available – English version: open.spotify.com/episode/0lfgzB… Please share! Thank you! 

In a large international study of more than 7000 patients with #OvarianCancer, we found that combined loss of RB1 protein & BRCA gene mutation predicts 🔼 immunologic responses and long-term survival in the high-grade serous subtype. Online NOW @CCR_AACR doi.org/10.1158/1078-0…

Read the latest research from the Christie lab @PeterMacRes on MHCII and whole genome duplication in ovarian cancer, published with @SpringerNature in @NatureComms nature.com/articles/s4146…

Great to speak with #9News yesterday along with @ocrfaustralia CEO Robin Penty on raising #ovariancancer awareness and much needed funds for research.

@MeagherNicki @djmarsh24 @ocrfaustralia @DaffodilCentre @9NewsSyd @sophie_walsh9 You’re becoming a celebrity 🤭🤩 that’s awesome!!

@DaffodilCentre @annapoids @nhmrc @WestmeadInst @CCNewSouthWales @syd_health Amazing news @annapoids 👏

Congratulations to @annapoids on securing a $2.7 million @nhmrc Investigator Grant in Ovarian Cancer research 🥳 Read more about Anna DeFazio's work here - daffodilcentre.org/people/anna-de… @WestmeadInst @CCNewSouthWales @syd_health

We determined authorship order using the Academic Wheel of Privilege (adapted from @sylviaduckworth). We examined our degree of privilege/marginalization in academia and society through a scoring system. Authors with fewer “privileges points” were prioritized in the author list.

Exploring rare ovarian cancer histotypes as part of an international collaboration. So important as these neglected groups of patients have limited risk predictions & treatment options. Check out our preprint for genetic insights and stay tuned for more! medrxiv.org/content/10.110…

What happens in the #tumormicroenvironment during chemotherapy in #ovariancancer ? Check out our new preprint: biorxiv.org/cgi/content/sh…

A great comment emphasizing the importance of using technologies that capture how tumour cells, immune cells, and the surrounding tissue interact in ovarian cancer. #Fun" target="_blank" rel="nofollow noopener">nature.com/articles/s4429…

Thrilled to contribute to this incredible project and grateful to our scientific journalist for sharing our work with a broader audience. Making research accessible to everyone is crucial! #ovariancancerawareness crio.einstein.br/entendendo-o-c…

NONE. ZERO. ZIP. NADA. 🎉 what a wonderful highlight to show the importance of HPV vaccination (critical for all genders) to halt the spread of deadly cancers.

The FDA has approved pembrolizumab with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer, based on a PFS benefit demonstrated in the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial: fda.gov/drugs/resource…

Do you want to learn computation as a wet biologist? I shared my experience in this podcast spreaker.com/episode/ep-27-… by @singlecellworld

Research continually evolves in amazing ways 👏

11 clinical trials that will shape medicine in 2024 - from base editing and a vaccine against HIV to AI tools for lung cancer and patient triage. Part of our Year in Review, by Paul Webster and @edbites nature.com/articles/s4159…

Excited to share my opinion piece on rethinking culture to unlock the potential of research Grateful to @HyperAHA & editors @LabTouyz & @endocelldoc for the support A 🧵 about why I wrote this & why it matters ahajournals.org/doi/10.1161/HY…

Falling behind: postdocs in their thirties tire of putting life on hold. Read the results of Nature’s second global survey of postdoctoral researchers go.nature.com/3Qtd4hI

🙌INTERLACE trial - induction chemotherapy + chemoXRT vs chemoXRT alone in locally advanced #CervicalCancer ✅🤩Compliance was good Induction yielded increased Progression free survival: HR 0.65 (p-0.013) Overall survival: HR 0.61 (p=0.04) #gyncsm #radonc #ESMO2023

In a Review now published online, Ana Veneziani, Eduardo Gonzalez-Ochoa, Husam Alqaisi, Ainhoa Madariaga, Gita Bhat, Marjan Rouzbahman, Suku Sneha & Amit Oza provide a comprehensive overview on the heterogeneity and treatment landscape of #ovariancancer nature.com/articles/s4157…